Alnylam Pharmaceuticals Inc
Latest Alnylam Pharmaceuticals Inc News and Updates
Inside the Fidelity Growth Company Fund Portfolio
FDGRX’s core sectors are information technology, consumer discretionary, and healthcare. The first two sectors make up a little over 60% of the portfolio.
Alnylam Pharmaceuticals: Developing Therapies for Hereditary ATTR Amyloidosis
Alnylam Pharmaceuticals (ALNY) is currently developing three investigational therapies—Patisiran, Revusiran, and ALN-TTRsc02—for the treatment of patients with hereditary ATTR amyloidosis.
Givosiran May Become Major Growth Driver for Alnylam Pharmaceuticals
On September 7, 2017, Alnylam Pharmaceuticals (ALNY) announced that it had reached an agreement with the US Food and Drug Administration (or FDA) related to the design of the phase three program for investigational RNAi therapeutic Givosiran.
ALNY Should Complete Revusiran’s Endeavour Trial Enrollment in Late 2016
If the Endeavour study results in positive data, Alnylam Pharmaceuticals may become a major rare disease player like its peers United Therapeutics (UTHR) and Vertex Pharmaceuticals.
What Moves Did FDGRX Make Leading Up to 1Q16?
FDGRX’s assets were invested across 394 holdings as of March 2016, two more than a quarter ago. It was managing assets worth $37.8 billion as of March’s end.
